Literature DB >> 21464082

Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

M J Callaghan1, S Lewis, M Sadarangani, S E S Bailey, H Chan, D J P Ferguson, J P Derrick, I Feavers, M C Maiden, A J Pollard.   

Abstract

Neisseria meningitidis causes half a million cases of septicemia and meningitis globally each year. The opacity (Opa) integral outer membrane proteins from N. meningitidis are polymorphic and highly immunogenic. Particular combinations of Opa proteins are associated with the hyperinvasive meningococcal lineages that have caused the majority of serogroup B and C meningococcal disease in industrialized countries over the last 60 years. For the first time, this genetic structuring of a diverse outer membrane protein family has been used to select a novel combination of representative antigens for immunogenicity testing. Fourteen recombinant Opa variants were produced and used in murine immunizations inducing an increase in specific antimeningococcal total IgG levels. All 14 Opa proteins elicited bactericidal antibodies against at least one hyperinvasive meningococcal isolate, and most isolates from each hyperinvasive lineage were killed by at least one Opa antiserum at a titer of 1:16 or greater. Cross-reactive bactericidal antibody responses were observed among clonal complexes. A theoretical coverage of 90% can be achieved by using a particular combination of 6 Opa proteins against an isolate collection of 227 recent United Kingdom disease cases. This study indicates the potential of Opa proteins to provide broad coverage against multiple meningococcal hyperinvasive lineages.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464082      PMCID: PMC3191958          DOI: 10.1128/IAI.01338-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Authors:  Rachel Urwin; Joanne E Russell; Emily A L Thompson; Edward C Holmes; Ian M Feavers; Martin C J Maiden
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

3.  An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues.

Authors:  J Finne; D Bitter-Suermann; C Goridis; U Finne
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

4.  Immunologic response of man to group B meningococcal polysaccharide vaccines.

Authors:  F A Wyle; M S Artenstein; B L Brandt; E C Tramont; D L Kasper; P L Altieri; S L Berman; J P Lowenthal
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

5.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

6.  Critical determinants of host receptor targeting by Neisseria meningitidis and Neisseria gonorrhoeae: identification of Opa adhesiotopes on the N-domain of CD66 molecules.

Authors:  M Virji; D Evans; A Hadfield; F Grunert; A M Teixeira; S M Watt
Journal:  Mol Microbiol       Date:  1999-11       Impact factor: 3.501

7.  Carcinoembryonic antigen family receptor specificity of Neisseria meningitidis Opa variants influences adherence to and invasion of proinflammatory cytokine-activated endothelial cells.

Authors:  P Muenzner; C Dehio; T Fujiwara; M Achtman; T F Meyer; S D Gray-Owen
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

8.  Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes.

Authors:  Ian C Boulton; Scott D Gray-Owen
Journal:  Nat Immunol       Date:  2002-02-19       Impact factor: 25.606

9.  Conformational analysis of opacity proteins from Neisseria meningitidis.

Authors:  Marien I de Jonge; Martine P Bos; Hendrik J Hamstra; Wim Jiskoot; Peter van Ulsen; Jan Tommassen; Loek van Alphen; Peter van der Ley
Journal:  Eur J Biochem       Date:  2002-11

10.  Interactions of Neisseria gonorrhoeae with mature human macrophage opacity proteins influence production of proinflammatory cytokines.

Authors:  B L Makepeace; P J Watt; J E Heckels; M Christodoulides
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

View more
  12 in total

1.  Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.

Authors:  Kay O Johswich; Shannon E McCaw; Lea Strobel; Matthias Frosch; Scott D Gray-Owen
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.

Authors:  Serena Giuntini; Donald C Reason; Dan M Granoff
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

3.  Vaccines against gonorrhea: current status and future challenges.

Authors:  Ann E Jerse; Margaret C Bash; Michael W Russell
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

4.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

5.  Quantitative Proteomics of the 2016 WHO Neisseria gonorrhoeae Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants.

Authors:  Fadi E El-Rami; Ryszard A Zielke; Teodora Wi; Aleksandra E Sikora; Magnus Unemo
Journal:  Mol Cell Proteomics       Date:  2018-10-23       Impact factor: 5.911

6.  Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.

Authors:  Ojas H Mehta; Gunnstein Norheim; J Claire Hoe; Christine S Rollier; Jerry C Nagaputra; Katherine Makepeace; Muhammad Saleem; Hannah Chan; David J P Ferguson; Claire Jones; Manish Sadarangani; Derek W Hood; Ian Feavers; Jeremy P Derrick; Andrew J Pollard; E Richard Moxon
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

7.  Contrasting within- and between-host immune selection shapes Neisseria Opa repertoires.

Authors:  Eleanor R Watkins; Yonatan H Grad; Sunetra Gupta; Caroline O Buckee
Journal:  Sci Rep       Date:  2014-10-09       Impact factor: 4.379

8.  Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.

Authors:  Manish Sadarangani; J Claire Hoe; Martin J Callaghan; Claire Jones; Hannah Chan; Katherine Makepeace; Hélène Daniels-Treffandier; Mary E Deadman; Christopher Bayliss; Ian Feavers; Peter van der Ley; Andrew J Pollard
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.

Authors:  Claire Jones; Manish Sadarangani; Susan Lewis; Isabelle Payne; Muhammad Saleem; Jeremy P Derrick; Andrew J Pollard
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

Review 10.  Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.

Authors:  Jennifer L Edwards; Michael P Jennings; Michael A Apicella; Kate L Seib
Journal:  Crit Rev Microbiol       Date:  2016-01-23       Impact factor: 7.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.